Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A. Attolico I, et al. Among authors: pavone v. Biol Blood Marrow Transplant. 2012 Feb;18(2):241-9. doi: 10.1016/j.bbmt.2011.07.014. Epub 2011 Jul 24. Biol Blood Marrow Transplant. 2012. PMID: 21791194 Free article. Clinical Trial.
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A. Basile A, et al. Among authors: pavone v. J Pathol. 2013 Jan;229(1):87-98. doi: 10.1002/path.4081. Epub 2012 Oct 1. J Pathol. 2013. PMID: 22847671 Free article.
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N. Mele G, et al. Among authors: pavone v. Leuk Res. 2015 Mar;39(3):279-83. doi: 10.1016/j.leukres.2014.12.007. Epub 2014 Dec 23. Leuk Res. 2015. PMID: 25636354
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Donatella Vincelli I, Antonia Martino E, Vigna E, Botta C, Bruzzese A, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Pia Falcone A, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Musto P, De Stefano V, Musso M, Teresa Petrucci M, Offidani M, Neri A, Di Renzo N, Di Raimondo F, Boccadoro M, Cavo M, Gentile M. Morabito F, et al. Among authors: pavone v. Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 2021 Nov 9. Eur J Haematol. 2022. PMID: 34716957 Free article.
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.
Mele G, Cascavilla N, Di Renzo N, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Palazzo G, Palumbo G, Reddiconto G, Rossini B, Specchia G, Musto P, Pastore D. Mele G, et al. Among authors: pavone v. Ann Hematol. 2022 Aug;101(8):1727-1739. doi: 10.1007/s00277-022-04857-0. Epub 2022 May 19. Ann Hematol. 2022. PMID: 35587825
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Vincelli ID, Martino EA, Vigna E, Bruzzese A, Mendicino F, Botta C, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Falcone AP, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Iaccino E, Mimmi S, Curci P, Gamberi B, Musto P, De Stefano V, Musso M, Petrucci MT, Offidani M, Di Raimondo F, Boccadoro M, Cavo M, Neri A, Gentile M. Morabito F, et al. Among authors: pavone v. Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022. Front Oncol. 2022. PMID: 35924160 Free PMC article.
UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis.
Locri F, Dal Monte M, Aronsson M, Cammalleri M, De Rosa M, Pavone V, Kvanta A, Bagnoli P, André H. Locri F, et al. Among authors: pavone v. J Mol Med (Berl). 2019 Sep;97(9):1273-1283. doi: 10.1007/s00109-019-01794-w. Epub 2019 Jun 26. J Mol Med (Berl). 2019. PMID: 31243519 Free PMC article.
447 results